SCHEMBL6983193

SCHEMBL6983193

Cc1noc(-c2c(-c3ccccc3)noc2C)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.67
PTGS1 P23219 6/20 0.67
MAPT P10636 4/20 0.57
KMT2A Q03164 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
GABRA5 P31644 1/20 0.52
IRS1 P35568 1/20 0.51
MT-CO2 P00403 3/20 0.50
ADORA3 P0DMS8 2/20 0.50
ADORA1 P30542 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
LMNA P02545 1/20 0.50
CA3 P07451 1/20 0.50
ADRB2 P07550 1/20 0.50
ADRB1 P08588 1/20 0.50
CYP3A4 P08684 1/20 0.50
CHRM1 P11229 1/20 0.50
ADRA2B P18089 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6979314 0.82 PTGS2 (0.59) PTGS2PTGS1MAPTKMT2ANPSR1
SCHEMBL5431928 0.81 NOTUM (0.63) PTGS2PTGS1MAPTKMT2ANPSR1
SCHEMBL5428577 0.81 PTGS2 (0.58) PTGS2PTGS1MAPTKMT2ANPSR1
SCHEMBL2277199 0.81 PTGS2 (1.00) PTGS2PTGS1MAPTKMT2ANPSR1
SCHEMBL5418130 0.79 KMT2A (0.58) PTGS2PTGS1MAPTKMT2ANPSR1
SCHEMBL806849 0.79 ACHE (0.66) MAPTGABRA5ADORA1LMNAL3MBTL1
SCHEMBL1930084 0.77 L3MBTL1 (0.67) PTGS2PTGS1MAPTKMT2ANPSR1
SCHEMBL8565210 0.76 GABRA5 (0.43) PTGS2PTGS1MAPTKMT2AGABRA5
SCHEMBL4587731 0.75 PTGS2 (0.80) PTGS2PTGS1MAPTKMT2AMT-CO2
SCHEMBL30253815 0.75 PTGS2 (0.63) PTGS2PTGS1MAPTKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183276-B2 Therapeutic agents MERCK SHARP & DOHME CORP. 2012-05-22 US disclosed
US-20100324029-A1 THERAPEUTIC AGENTS MERCK SHARP & DOHME CORP. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324029-A1 THERAPEUTIC AGENTS PSEN2, PSEN1, BACE2 PTGS2 266/4885PTGS1 398/4885MAPT 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.